Project Grant HT94252410518

This Project Grant award of $1,986,332.00 was provided by the Agency for Toxic Substances and Disease Registry (ATSDR) under the State Capacity Building program (CFDA 93.240). The goal of the project is to investigate a panel of persistent environmental toxicant exposures in the central nervous system (CNS) tissue of military veterans to identify etiological factors contributing to the development of amyotrophic lateral sclerosis (ALS). The primary work includes developing and applying...

The University of Massachusetts Medical School was awarded a $836,992 Project Grant by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on August 1, 2025, will fund research to investigate the effects of military-associated environmental toxins on motor neurons and glial cells in sporadic amyotrophic lateral sclerosis (ALS). The research aims to transform healthcare for military service members, veterans, and the broader...

The Department of Defense's Defense Health Agency awarded a $1,035,460 Project Grant to Brigham & Women's Hospital Inc. to conduct research on "TREATMENT OF ALS BY NASAL ADMINISTRATION OF ANTI-CD3 MONOCLONAL ANTIBODY TO MODULATE INFLAMMATORY MICROGLIA AND PREVENT MOTOR NEURON DEGENERATION". This grant, funded under the Military Medical Research and Development program (CFDA 12.420), aims to develop a new treatment approach for amyotrophic lateral sclerosis (ALS) by modulating...

The Department of Defense's Defense Health Agency awarded a $921,600 Project Grant to The General Hospital Corporation (Massachusetts General Hospital) to research the "Therapeutic Effects of Sulfide Catabolism and Novel Trisulfide Compounds for Amyotrophic Lateral Sclerosis." The grant, under the Military Medical Research and Development program (CFDA 12.420), supports foundational biomedical research aimed at developing novel treatments for amyotrophic lateral sclerosis (ALS)....

The Defense Health Agency awarded a $929,948 Project Grant to The Washington University in St. Louis, Missouri to support the research project "TARGETING TDP-43 MITOCHONDRIAL MISLOCALIZATION IN ALS". This grant is funded through the Military Medical Research and Development program (CFDA 12.420), which supports biomedical research aimed at improving the health and care of military service members, veterans, and their families. The research project will investigate mitochondrial...

The Van Andel Research Institute was awarded a $950,000 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 30, 2023 to September 29, 2025 to establish the neuroprotective potential of C9ORF72 hypermethylation in repeat expansion-caused ALS. Through this award, the grantee will investigate medical solutions for the battlefield by transforming health care for service members and the...

The Department of the Army Medical Command awarded a $1,180,437 Project Grant to the University of California, Los Angeles (UCLA) under the Military Medical Research and Development program (CFDA 12.420). The grant supports UCLA's research to evaluate circulating cell-free DNA as a biomarker for diagnosing and tracking the progression of amyotrophic lateral sclerosis (ALS). The award began on March 1, 2024 and is scheduled for completion by February 28, 2026. Through this Project Grant, UCLA...

The Defense Health Agency awarded a $458,516 Project Grant to Mayo Clinic Jacksonville to support research titled "NOVEL THERAPEUTICS TARGETING STRESS GRANULES FOR C9ORF72-MEDIATED ALS." The grant period runs from February 1, 2021 through June 30, 2022. The grant supports research into novel therapeutics targeting stress granules for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the C9orf72 gene. This work falls under the Military Medical Research and...

This federal Project Grant award of $1,072,079.00 from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) supports research by the Massachusetts Institute of Technology (MIT) to develop diagnostic biomarkers for clinical subtypes of amyotrophic lateral sclerosis (ALS). The research aims to advance the understanding and treatment of ALS, a neurological disorder, with potential benefits for military service members and the broader public....

This Project Grant award of $1,210,500.00 from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by Mayo Clinic in Rochester, MN to explore novel biomarkers for amyotrophic lateral sclerosis (ALS). The 3-year grant, effective April 1, 2025, will utilize a multiomics approach including immunoprofiling, extracellular vesicle analysis, and TDP-43 aggregation assays to identify potential new diagnostic and prognostic markers for...